Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability
worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment …

Background Treatment guidelines recommend the use of inhaled long-acting
bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with …

Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of
death in the world and its incidence and prevalence is on the rise. It is evident that COPD is …

Background Tiotropium via the HandiHaler device is an established long-acting,
anticholinergic bronchodilator that prevents exacerbations and improves lung function in …

Background To further assess the safety profile of the fixed-dose combination of indacaterol
and glycopyrronium (QVA149) and its monocomponents; we investigated the impact of …

Background Long-acting bronchodilators are the cornerstone of pharmacologic treatment of
COPD. The new combination of long-acting muscarinic antagonist (LAMA) tiotropium (TIO) …

Chronic obstructive pulmonary disease (COPD) is characterized by chronic respiratory
symptoms, such as breathlessness and chronic productive cough, limited exercise …

Bronchodilators are the most important drugs used for the treatment of chronic obstructive
pulmonary disease (COPD). In particular, these therapeutic agents are mostly long-acting …

Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and
mortality worldwide, is a major problem for public health. It is predicted that its burden will …

Background Tiotropium bromide, once daily, long-acting anticholinergic bronchodilator is
either administered by handihaler metered dose inhaler or by respimat soft mist inhaler. It …